FIELD: medicine, oncology, dermatology.
SUBSTANCE: the present innovation deals with treating mammalians due to introducing nonpsychotropic compounds - tetrahydrocannabinol derivatives, adjulemic acid derivative, in particular. The innovation suggested enables to either decrease or prevent cell proliferation at the following diseases: psoriasis, tumors along with low toxicity level of therapy conducted.
EFFECT: higher efficiency.
11 cl, 4 dwg, 1 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
CANNABINOID DRUGS | 2001 |
|
RU2273476C2 |
SATURATED ACID ANALOGS FOR CANCER TREATMENT | 2001 |
|
RU2283105C2 |
ALPHA-DERIVATIVES OF CIS-MONOUNSATURATED FATTY ACIDS APPLICABLE AS THERAPEUTIC AGENT | 2009 |
|
RU2531353C2 |
ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS FOR USING IT | 2006 |
|
RU2448703C2 |
APPLICATION OF 2-HYDROXYDERIVATIVES OF POLYUNSATURATED FATTY ACIDS AS MEDICATIONS | 2010 |
|
RU2513995C2 |
NEW CANNABIDIOL QUINONE DERIVATIVES | 2014 |
|
RU2667504C2 |
ANTI-TUMOUR EFFECTS OF COMBINATIONS OF CANNABIS COMPOUNDS | 2009 |
|
RU2546284C2 |
SELF-DELIVERED RNAI COMPOUNDS OF REDUCED SIZE | 2011 |
|
RU2615143C2 |
ENANTIOMERS-2-HYDROXY-DERIVATIVES OF FATTY ACIDS | 2012 |
|
RU2637937C2 |
ENANTIOMERS OF 2-HYDROXY DERIVATIVES OF FATTY ACIDS | 2012 |
|
RU2687967C2 |
Authors
Dates
2006-03-27—Published
2001-05-17—Filed